OverTheCounterToday

"The Tan Sheet" News Roundup: P&G Pares Exec Ranks, Afexa Bidding War, Saw Palmetto Study

 

This news roundup is brought to you by "The Tan Sheet," your source for the most in-depth news and analysis from the world of OTC drugs and nutritionals. For information on a 30-day free trial subscription, click here.

Also, check out "The Tan Sheet" on Twitter and Facebook.

This Week In OTCs And Nutritionals: OTC Reimbursement Technology, NDI Notification Costs, Revo BIolabs

Could a prepaid insurance reimbursement card for nonprescription drug purchases help facilitate Rx-to-OTC switches? "The Tan Sheet" examines the possibility in this week's issue, with a cover story about Medagate Corp.'s OTCNetwork benefits program platform.

Our Sept. 26 issue also takes a look at the Council for Responsible Nutrition's push for a revised estimate for how long it takes a supplement firm to compile and submit a new dietary ingredient notification to FDA; the agency estimates 20 hours, while CRN says the process is more like 100 to 350 hours.

There's also much more from "The Tan Sheet," including a profile of supplement industry veteran Elliott Balbert's latest venture, Revo Biolabs. Plus, we've got stories on FDA's proposed SPF cap for sunscreens, GlaxoSmithKline's partnership with Formula One racing firm McLaren, and a first glimpse at last week's Natural Products Expo East in Baltimore.

 

Make "The Tan Sheet" your go-to weekly source for OTC and nutritional news and analysis. Click here for more information on a free 30-day trial subscription.

We're on Facebook! Friend "The Tan Sheet" here.

We're on Twitter! Subscribe to tweets from TheTanSheet here.

Glaxo OTC Suitors Said To Include Prestige Brands, Stada, Private Equity

 
GlaxoSmithKline (led by CEO Andrew Witty, pictured above) is dealing with several interested parties from both pharma and private equity in the process of unloading a large chunk of its consumer health care brands -- including alli, Beano and FiberChoice -- according to media reports. ("The Tan Sheet" took an in-depth look at the products up for grabs in an April story, posted here.)

RTTNews says Prestige Brands is making a play for the 19 OTC brands for sale, with the backing of Blackstone Group. In return for financing the acquisition, estimated in the range of $2.3 billion to $3.1 billion, Blackstone would take a stake in Prestige, RTTNews reports.

This Week In OTCs And Nutritionals: Asthma Drug Switch Possibilities, J&J Consumer Comeback, AHPA's NDI Congress

 

The cover story for our Sept. 19 issue examines the possibility of Rx-to-OTC switches for asthma drugs, including GlaxoSmithKline's Advair and Merck's Singulair, once they lose patent protection.

Looking inside this week's "Tan Sheet", we report on what Johnson & Johnson is telling market analysts about the resurrection of its consumer business following 2010's recalls. There's also in-depth coverage of the American Herbal Products Association's recent NDI Congress in Chicago, at which supplement industry stakeholders emphasized the importance of a unified response to FDA's new dietary ingredient notification draft guidance.

Additionally, we've got stories on U.S. Pharmacopeia's monograph modernization initiative, an FDA guidance document on self-selection studies for OTC drugs, and what Sen. Tom Harkin has planned for securing the pharmaceutical supply chain.

Make "The Tan Sheet" your go-to weekly source for OTC and nutritional news and analysis. Click here for more information on a free 30-day trial subscription.

We're on Facebook! Friend "The Tan Sheet" here.

"The Tan Sheet" News Roundup: Pfizer Delays Nutritionals Sale, Ron Paul Supplement Bill, Pharmavite In 'Bama

 

 
 

This news roundup is brought to you by "The Tan Sheet," your source for the most in-depth news and analysis from the world of OTC drugs and nutritionals. For information on a 30-day free trial subscription, click here. 

 

This Week In OTCs And Nutritionals: Aurobindo In Russia, Telometrics In Anti-Aging, Drugs And Supplements On Facebook

 
“The Tan Sheet” this week looks at Indian firm Aurobindo Pharma’s entry into Russia’s surging consumer health product market with a joint venture with Diod to market OTC and generic drugs. Also in this issue, we look at Telometrics’ bid for part of the market for products leveraging research on telomeres and purporting to combat aging with its $600 Vital-25 Anti-Aging Formula supplement.

In addition, we report on drug firms’ options for continuing Facebook campaigns after the influential networking site revoked their exclusive privilege to block consumer comments on their walls and on advertising opportunities for vitamin and supplement firms’ now that Facebook is accepting ads for their products.

[Make "The Tan Sheet" your go-to weekly source for OTC and nutritional news and analysis. Click here for more information on a free 30-day trial subscription.]

Tweeting The NDI Congress

On Thursday, Sept. 8, follow TheTanSheet on Twitter for live updates from the American Herbal Products Association's New Dietary Ingredient Congress in Chicago... Twitter.com/TheTanSheet

"The Tan Sheet" Presents: OTC/Nutritional News Roundup

This news roundup is brought to you by "The Tan Sheet," your source for the most in-depth news and analysis from the world of OTC drugs and nutritionals. For information on a 30-day free trial subscription, click here. 

This Week In OTCs And Nutritionals: Apricus Biosciences, Listerine Suit, Nutrition 21 Bankruptcy

 
In our Sept. 5 issue, "The Tan Sheet" profiles Apricus Biosciences, a start-up looking to apply its proprietary delivery technology to OTC topicals. We've also got news on Nutrition 21's Chapter 11 bankruptcy filing, the culmination of the ingredient company's unsuccessful foray into finished supplement products. 

Additionally, this week's edition features a pair of Johnson & Johnson stories, one detailing the firm's latest OTC divestment -- its sale of Monistat to Insight Pharmaceuticals -- and the other examining the aftermath of a study linking Listerine to oral cancer and a discontinued co-marketing deal that led to a lawsuit against J&J.

[Make "The Tan Sheet" your go-to weekly source for OTC and nutritional news and analysis. Click here for more information on a free 30-day trial subscription.]